Victor G. Vogel, MD, of the Geisinger Medical Center and an editor of the Journal of the National Cancer Institute, called the reductions in breast cancer and stroke incidence "dramatic" and considered that, though more data about the long-term effects of lasofoxifene was needed, the drug just may be the "tipping point in breast cancer prevention."
I recently attended my local Inventors Association (Inventors Alliance in Northern California) and noticed that Inventors kept asking Andrew Krauss (President of Inventors Alliance) about the differences between Manufacturing and Licensing a product. New Inventors were confused about what these terms meant and wanted to learn more about the factors to consider when deciding which way to go for their own product. So I thought I'd take a minute to discuss both options as this comes up all of the time in my workshops and classes as well.
The study, undertaken at the University of Iowa and Indiana University, not only reinforces what we've already learned in behavioral psychology, that we notice what we are primed to notice, but also that we don't notice what we are not primed to notice.
Another study from the Women's Health Initiative 11 year follow-up has revealed, for the first time, that women who receive hormone replacement therapy (HRT) are twice as likely to die from breast cancer than those who do not receive the therapy. This information is contrary to the prevailing notion that estrogen plus progesterone therapy has little impact on severity or mortality of breast cancer.